US2007198080A1PendingUtilityA1

Coatings including an antioxidant

48
Assignee: DING NIPriority: Jul 25, 2005Filed: Sep 27, 2006Published: Aug 23, 2007
Est. expiryJul 25, 2025(expired)· nominal 20-yr term from priority
Inventors:Ni DingLeslie Coleman
Y10T428/1307A61L 31/10
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A coating including an antioxidant or a combination of antioxidant and another bioactive agent on a medical device is described.

Claims

exact text as granted — not AI-modified
1 . A medical device comprising a coating, the coating comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof, 
 wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and    wherein the natural antioxidant is not Vitamin E.    
   
   
       2 . The medical device of  claim 1 , wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.  
   
   
       3 . The medical device of  claim 2 , wherein the SODm is attached to the surface of the coating.  
   
   
       4 . The medical device of  claim 3 , wherein the SODm is attached to a polymer in the coating.  
   
   
       5 . The medical device of  claim 1 , wherein the coating further comprises a bioactive agent.  
   
   
       6 . The medical device of  claim 1 , wherein the coating further comprises heparin.  
   
   
       7 . The medical device of  claim 5 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.  
   
   
       8 . The medical device of  claim 1 , which is a stent.  
   
   
       9 . The medical device of  claim 1 , which is a bioabsorbable stent.  
   
   
       10 . The medical device of  claim 1 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.  
   
   
       11 . A bioabsorbable medical device comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof, 
 wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and    wherein the natural antioxidant is not Vitamin E.    
   
   
       12 . The bioabsorbable medical device of  claim 11 , wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.  
   
   
       13 . The bioabsorbable medical device of  claim 11 , wherein the SODm is attached to the surface of the bioabsorbable medical device.  
   
   
       14 . The bioabsorbable medical device of  claim 11 , wherein the bioabsorbable medical device further comprises a bioactive agent.  
   
   
       15 . The bioabsorbable medical device of  claim 11 , wherein the bioabsorbable medical device further comprises heparin.  
   
   
       16 . The medical device of  claim 14 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.  
   
   
       17 . The bioabsorbable medical device of  claim 11 , which is a stent.  
   
   
       18 . The bioabsorbable medical device of  claim 11 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.  
   
   
       19 . A method comprising 
 applying to a medical device a formulation comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof, and    forming a coating of the formulation on the medical device,    wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA),    wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and    wherein the natural antioxidant is not Vitamin E.    
   
   
       20 . The method of  claim 19 , wherein the antioxidant is selected from ascorbic acid, folic acid and B vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.  
   
   
       21 . The method of  claim 20 , wherein the SODm is attached to the surface of the coating.  
   
   
       22 . The method of  claim 20 , wherein the SODm is attached to a polymer in the coating.  
   
   
       23 . The method of  claim 19 , wherein the formulation further comprises a bioactive agent.  
   
   
       24 . The method of  claim 19 , wherein the formulation further comprises heparin.  
   
   
       25 . The method of  claim 24 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate; midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.  
   
   
       26 . The method of  claim 19 , wherein the medical device is a stent.  
   
   
       27 . The method of  claim 19 , wherein the medical device is a bioabsorbable stent.  
   
   
       27 . The method of  claim 19 , wherein forming the coating comprises 
 baking the coating, and    sterilizing the coating.    
   
   
       28 . The method of  claim 27 , wherein the baking or sterilizing are conducted at a temperature between about 25° C. and about 55° C.  
   
   
       29 . The method of  claim 20 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.  
   
   
       30 . A method comprising implanting the medical device of  claim 1  into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.  
   
   
       31 . A method, comprising implanting the medical device of  claim 7  to the human being, into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.  
   
   
       32 . A method comprising implanting the medical device of  claim 8  into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.  
   
   
       33 . A medical device comprising a coating, the coating comprising at least two antioxidants, wherein one antioxidant is selected from BHT, BHA, Vitamin E, a SODm or a combination thereof.  
   
   
       34 . The medical device of  claim 33 , wherein the other antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, polyphenol antioxidants, apigenin or combinations thereof.  
   
   
       35 . The medical device of  claim 33 , wherein the SODm is attached to the surface of the coating.  
   
   
       36 . The medical device of  claim 35 , wherein the SODm is attached to a polymer in the coating.  
   
   
       37 . The medical device of  claim 33 , wherein the coating further comprises a bioactive agent.  
   
   
       38 . The medical device of  claim 33 , wherein the coating further comprises heparin.  
   
   
       39 . The medical device of  claim 37 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.  
   
   
       40 . The medical device of  claim 33 , which is a stent.  
   
   
       41 . The medical device of  claim 33 , which is a bioabsorbable stent.  
   
   
       42 . The medical device of  claim 33 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.  
   
   
       43 . A bioabsorbable medical device comprising at least two antioxidants, wherein one antioxidant is selected from BHT, BHA, Vitamin E, a SODm or a combination thereof.  
   
   
       44 . The bioabsorbable medical device of  claim 43 , wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.  
   
   
       45 . The bioabsorbable medical device of  claim 43 , wherein the SODm is attached to the surface of the bioabsorbable medical device.  
   
   
       46 . The bioabsorbable medical device of  claim 43 , wherein the bioabsorbable medical device further comprises a bioactive agent.  
   
   
       47 . The bioabsorbable medical device of  claim 43 , wherein the bioabsorbable medical device further comprises heparin.  
   
   
       48 . The medical device of  claim 46 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.  
   
   
       49 . The bioabsorbable medical device of  claim 43 , which is a stent.  
   
   
       50 . The bioabsorbable medical device of  claim 43 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.